08:01 AM EDT, 06/27/2025 (MT Newswires) -- LSL Pharma Group (LSL.V) said Friday that it secured $17.5 million in new financing from Caisse Populaire Desjardins des Patriotes and BDC.

The funding comprises a new $7.5 million operating line of credit from Desjardins, a $4.2 million increase from the prior combined line of credit from TD Bank and Scotia Bank (BNS.TO).

LSL also announced a new $10 million pari-passu term loan from BDC and Desjardins, with closing expected July 7. The company will use the funds to reimburse loans and debts, as well as for capital expenditures.

"The new line of credit and term loan will significantly increase our working capital flexibility by providing us with in excess of $6 million of additional financing not allocated to loans/debt repayments", said Luc Mainville, CFO and executive vice-president of LSL.

LSL's share price jumped 5.4% on Thursday to $0.39 on the TSXV.